Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 1
2014 2
2019 1
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Interventions for non-metastatic squamous cell carcinoma of the skin.
Lansbury L, Leonardi-Bee J, Perkins W, Goodacre T, Tweed JA, Bath-Hextall FJ. Lansbury L, et al. Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD007869. doi: 10.1002/14651858.CD007869.pub2. Cochrane Database Syst Rev. 2010. PMID: 20393962 Free PMC article. Review.
OBJECTIVES: To assess the effects of treatments for primary non-metastatic squamous cell carcinoma of the skin. SEARCH STRATEGY: In February 2010 we searched for relevant trials in The Cochrane Skin Group Specialised Register, The Cochrane Library (Iss …
OBJECTIVES: To assess the effects of treatments for primary non-metastatic squamous cell carcinoma of the skin. …
Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yin G, Guo W, Duan H, Huang Z. Yin G, et al. Clin Otolaryngol. 2021 Sep;46(5):1013-1020. doi: 10.1111/coa.13772. Epub 2021 Apr 21. Clin Otolaryngol. 2021. PMID: 33765363
BACKGROUND: The use of immunotherapy to treat recurrent/metastatic squamous cell carcinoma of the head and neck has become a popular research topic in recent years, and many clinical trials have been carried out. ...CONCLUSIONS AND SIGNIFICANCE: Treatm …
BACKGROUND: The use of immunotherapy to treat recurrent/metastatic squamous cell carcinoma of the head and neck …
Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma.
Petzold A, Steeb T, Wessely A, Schatton T, Berking C, Heppt MV. Petzold A, et al. Eur J Cancer. 2022 Jul;170:42-53. doi: 10.1016/j.ejca.2022.03.035. Epub 2022 May 17. Eur J Cancer. 2022. PMID: 35594611
ICB showed the highest median PFS (mPFS 9.9 months (95% CI: 8.1-19.9)) and median OS (mOS not reached (95% CI: 31.5 months-not reached)) compared to chemotherapy (mPFS 3.0 months (95% CI: 2.2-4.8), mOS 12.6 months (95% CI: 9.6-15.8)), targeted therapy to epidermal growth factor ( …
ICB showed the highest median PFS (mPFS 9.9 months (95% CI: 8.1-19.9)) and median OS (mOS not reached (95% CI: 31.5 months-not reached)) com …
Temporal changes in the efficacy of chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
Winquist E, Al-Rasheedy I, Nichols AC, Palma DA, Stitt L. Winquist E, et al. Cancer Treat Rev. 2014 Oct;40(9):1073-9. doi: 10.1016/j.ctrv.2014.08.002. Epub 2014 Aug 27. Cancer Treat Rev. 2014. PMID: 25200522
BACKGROUND: Cytotoxic chemotherapy remains a standard treatment option for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN), but its effectiveness is debatable. ...
BACKGROUND: Cytotoxic chemotherapy remains a standard treatment option for patients with recurrent or metastatic squamous c …
For Whom the Bell's Toll: Recurrent Facial Nerve Paralysis, A Retrospective Study and Systematic Review of the Literature.
Chweya CM, Anzalone CL, Driscoll CLW, Lane JI, Carlson ML. Chweya CM, et al. Otol Neurotol. 2019 Apr;40(4):517-528. doi: 10.1097/MAO.0000000000002167. Otol Neurotol. 2019. PMID: 30870370
Diagnostic evaluation confirmed Melkersson-Rosenthal syndrome in four (7.5%) cases, neurosarcoidosis in two (3.7%), traumatic neuroma in one (1.9%), Ramsay Hunt syndrome in one (1.9%), granulomatosis with polyangiitis in one (1.9%), and neoplastic causes in three (5.7%) cases [fa …
Diagnostic evaluation confirmed Melkersson-Rosenthal syndrome in four (7.5%) cases, neurosarcoidosis in two (3.7%), traumatic neuroma in one …